Antitumor agent-70 (compound 8b) is a highly potent multi-targeted kinase inhibitor, particularly targeting c-Kit. It demonstrates remarkable anti-tumor activity and the ability to induce cell apoptosis. This compound also exhibits strong inhibition of multiple myeloma, with an IC 50 value of 0.12 μM. Therefore, Antitumor agent-70 holds great potential as an effective therapy for combating cancer, especially in cases involving c-Kit. [1]

Antitumor agent-70 (compound 8b) (0-50 μM, 24 hours) has excellent anti-tumor proliferative activity, especially against multiple myeloma cell RPMI8226 [1]. Antitumor agent-70 (compound 8b) (0-0.2 μM, 24 hours) arrests the cell cycle in G0/G1 phase [1]. Antitumor agent-70 (compound 8b) (0-0.2 μM, 24 hours) can induce apoptosis to inhibit cell proliferation by promoting ROS release cells [1]. Cell Proliferation Assay [1] Cell Line: Human myeloma cell line U266, Human multiple myeloma cell line RPMI8226, Human umbilical vein endothelial cells HUVEC Concentration: 0-50 μM Incubation Time: 24 hours Result: Showed anti-proliferative activity against U266, RPMI8226, HUVEC with an IC 50 value of 3.81 μM, 0.12 μM, 12.09 μM respectively. Cell Cycle Analysis [1] Cell Line: RPMI8226 Concentration: 0-0.2 μM Incubation Time: 24 hours Result: Showed a significant increase in the proportion of G0/G1 phase cells while S phase and G2/M phase decreased significantly. Apoptosis Analysis [1] Cell Line: RPMI8226 Concentration: 0-0.2 μM Incubation Time: 24 hours Result: Induced apoptosis rate increased with increasing concentration. Early apoptosis rate is higher than late apoptosis rate.